drugset / Trial / NCT01757236
Efficacy and Safety Study of Antibiotic Treatment to Treat Hip Prosthetic Joint Infection
Phase 2
Unknown
100 enrolled
University Hospital, Tours
International Clinical Trials Association · collabPfizer · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the efficacy of oral linezolid-rifampin combination therapy (over 4 or 6 weeks) versus the standard of care in the treatment of Gram-positive prosthetic hip joint infection with a one-stage surgical treatment.
Timeline
- Start
- 2012-10
- Primary completion
- 2016-04
- Completion
- 2016-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Clindamycin | Unknown | 600 mg | Oral |
| Subject | Linezolid | Other / unclassified | 600 mg | Intravenous |
| Comparator | Ofloxacin | Small molecule | 200 mg | Oral |
| Subject | Rifampin | Small molecule | 10 mg/kg | Oral |
| Subject | Rifampin | Small molecule | 15 mg/kg | Oral |
| Comparator | Sulfamethoxazole | Small molecule | 800 mg | Oral |
| Comparator | Trimethoprim | Small molecule | 160 mg | Oral |
| Background | Ceftriaxone | Other / unclassified | 2 g | Intravenous |
| Background | Vancomycin | Other / unclassified | 15 mg/kg | Intravenous |